Jade Biosciences, Inc. (NASDAQ:JBIO) Receives $20.80 Average PT from Brokerages

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.80.

A number of research firms recently weighed in on JBIO. Weiss Ratings restated a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. BTIG Research initiated coverage on shares of Jade Biosciences in a research report on Thursday, October 9th. They set a “buy” rating and a $28.00 target price on the stock. Guggenheim raised their price target on Jade Biosciences from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright initiated coverage on Jade Biosciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $25.00 target price for the company.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Deltec Asset Management LLC bought a new position in shares of Jade Biosciences during the 2nd quarter worth $157,000. Geode Capital Management LLC purchased a new stake in Jade Biosciences in the second quarter worth about $6,759,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Jade Biosciences in the second quarter worth about $71,000. Intech Investment Management LLC bought a new position in Jade Biosciences during the 2nd quarter worth about $230,000. Finally, Versant Venture Management LLC purchased a new position in Jade Biosciences during the 2nd quarter valued at about $15,243,000.

Jade Biosciences Stock Performance

JBIO stock opened at $14.70 on Friday. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $100.10. The company has a market cap of $724.86 million, a price-to-earnings ratio of -1.32 and a beta of 1.02. The business’s 50-day moving average is $13.77 and its two-hundred day moving average is $10.36.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09.

About Jade Biosciences

Jade Biosciences, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small?molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.